Pfizer Cash Flow from Investing Activities 2012-2026 | PFE
Pfizer annual/quarterly cash flow from investing activities history and growth rate from 2012 to 2026. Cash flow from investing activities can be defined as the total change in cash resulting from a companies investments
- Pfizer cash flow from investing activities for the quarter ending March 31, 2026 was $4.795B, a 12.16% increase year-over-year.
- Pfizer cash flow from investing activities for the twelve months ending March 31, 2026 was $17.946B, a 190% decline year-over-year.
- Pfizer annual cash flow from investing activities for 2024 was $2.652B, a 108.22% decline from 2023.
- Pfizer annual cash flow from investing activities for 2023 was $-32.278B, a 104.51% increase from 2022.
- Pfizer annual cash flow from investing activities for 2022 was $-15.783B, a 30% decline from 2021.
|
Pfizer Annual Cash Flow Investing (Millions of US $) |
|
|---|---|
| 2024 | $2,652 |
| 2023 | $-32,278 |
| 2022 | $-15,783 |
| 2021 | $-22,546 |
| 2020 | $-4,271 |
| 2019 | $-3,945 |
| 2018 | $4,525 |
| 2017 | $-4,740 |
| 2016 | $-7,791 |
| 2015 | $-2,980 |
| 2014 | $-5,654 |
| 2013 | $-10,544 |
| 2012 | $6,154 |
| 2011 | $1,843 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Large Cap Pharmaceutical | $153.074B | $62.579B |
| Pfizer Inc. is a research-based, global biopharmaceutical company. The company boasts a sustainable pipeline with multiple late-stage programs that can drive growth. Pfizer markets a wide range of drugs and vaccines. Its business comprises six business units - Oncology, Inflammation & Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. Pfizer spinned-off its Upjohn unit, its off-patent branded and generic established medicines business, and combined it with generic drugmaker Mylan to create a new generic pharmaceutical company called Viatris. The Consumer Healthcare (CHC) segment, an over-the-counter (OTC) medicines business, was merged with Glaxo's unit to form a new joint venture.?The Consumer Healthcare joint venture with Glaxo and the merger of Upjohn unit with Mylan has made Pfizer a smaller company with a diversified portfolio of innovative drugs and vaccines. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Eli Lilly (LLY) | United States | $887.629B | 38.81 |
| Johnson & Johnson (JNJ) | United States | $574.358B | 22.08 |
| AbbVie (ABBV) | United States | $367.673B | 20.79 |
| Roche Holding AG (RHHBY) | Switzerland | $318.782B | 0.00 |
| Merck (MRK) | United States | $299.893B | 13.54 |
| Novartis AG (NVS) | Switzerland | $293.951B | 17.16 |
| Novo Nordisk (NVO) | Denmark | $167.527B | 9.60 |
| Sanofi (SNY) | France | $114.048B | 10.56 |
| Bayer (BAYRY) | Germany | $46.178B | 8.70 |
| Innoviva (INVA) | United States | $1.760B | 5.88 |